Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Tafamidis for the treatment of TTR cardiac amyloidosis

Giampaolo Merlini • 14 Sep 2019
IMW 2019
Amyloidosis Multiple Myeloma Rare Diseases Tafamidis

Giampaolo Merlini, MD University of Pavia, Pavia, Italy, provides an overview of the use of tafamidis in the treatment of transthyretin cardiac amyloidosis at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Giampaolo Merlini

2:18
The potential of CAR-T therapy for the treatment of amyloidosis
Giampaolo Merlini • 10 May 2022
5:57
Treatment approaches for amyloidosis patients with advanced cardiac involvement
Giampaolo Merlini • 10 May 2022
3:23
Novel agents and clinical trials emerging for the treatment of AL amyloidosis
Giampaolo Merlini • 10 May 2022
3:33
Advances in AL amyloidosis
Giampaolo Merlini • 10 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals